CML and the WHO: Why?

By sjmartinez • December 13, 2023

Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker B. CML and the WHO: Why? J Clin Oncol. 2023 Dec 12:JCO2301689. doi: 10.1200/JCO.23.01689. Epub ahead of print. PMID: 38086008.

Tags: Hematology/Oncology, Publications

Related Posts

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer

Park W, Kasi A, Spira AI, Paz-Ares Rodríguez L, Herzberg BO, Pelster MS, Tolcher AW, Kuboki Y, Kitano S, Shoji H, Wang JS, Berlin JD,[...]

The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer

Cecchini M, Han SW, Lee S, Lee KW, Kopetz S, Mizrahi J, Hong YS, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao[...]

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C,[...]